Type 2 Diabetes
Conditions
Brief summary
The aim of the study is to assess the effect of Rotating Magnetic Therapy on blood glucose spectrum of type 2 diabetic patients with glargine therapy using flash glucose monitors
Interventions
Rotating Magnetic Therapy 30min/ Bid for 1 month
Sponsors
Majianhua
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Volunteer to participate and sign informed consent prior to the study * Patients with type 2 diabetes, who met WHO1999 diagnostic criteria, aged 18-70 years old, and were treated with insulin glargine alone and/or insulin glargine combined with oral hypoglycemic drugs, the treatment regimen was stable for more than 2 months * Fasting blood glucose ranged from 6.1 to 13.9mmolL, and postprandial (or random) blood glucose was \<22.2mmol/L. * Subjects can and are willing to conduct flash glucose monitoring and regular diet and exercise
Exclusion criteria
* Patients with insulin allergy * Patients treated with GLP-1a or DPP-4 inhibitors or multipoint subcutaneous insulin injection in the last three months * Impaired liver and kidney function with ALT 2.5 times higher than the upper limit of normal value and serum creatinine 1.3 times higher than the upper limit of normal value * Patients with metal foreign bodies or pacemakers * Patients with a history of surgery in magnetic therapy site within one year * Patients with obvious discomfort to magnetic therapy * Patients with bleeding or bleeding tendency * Patients with poor compliance and irregular diet and exercise * Patients with acute complications of diabetes, such as infection, diabetic ketoacidosis, hypertonic coma and so on, and patients with stress status within four weeks * Patients who are pregnant, breast-feeding, or intending to become pregnant * Any other apparent conditions or associated diseases determined by the investigator: severe cardiopulmonary, endocrine, neurological, tumor, other pancreatic diseases, history of mental illness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the standard deviation of blood glucose | 2 weeks | the difference of the standard deviation of blood glucose between the two groups assessed by FGM |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| mean blood glucose | 2 weeks | mean blood glucose between the two groups assessed by FGM |
| time in range | 2 weeks | time in range assessed by FGM |
Outcome results
None listed